Medicare Enrolled
Dr. Mohammad Riaz, MD
Medical Oncology · Katy, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Riaz from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Riaz?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Riaz
Dr. Mohammad Riaz is a medical oncology specialist in Katy, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Riaz performed 10,252 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Riaz received a total of $6,841 from 69 pharmaceutical and/or device companies across 362 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Riaz is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 41% volume in TX
$6,841 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗10,252
Medicare services
Top 41% in TX for medical oncology
Not available
Unique patients (not deduplicated)
$20
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 5,820 | $17 | $49 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,510 | $1 | $26 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
488 | $1 | $16 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
363 | $23 | $64 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
287 | $95 | $241 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
256 | $23 | $69 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
236 | $105 | $309 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
234 | $52 | $146 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
232 | $10 | $34 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
203 | $1 | $1 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
178 | $58 | $166 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
165 | $17 | $41 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 154 | $14 | $28 |
| New patient office visit, complex (60-74 min) | 44 | $171 | $478 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
37 | $49 | $153 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
23 | $11 | $59 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
22 | $110 | $343 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
13.8% high complexity
80.5% medium
5.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,841
Total received (2018-2024)
Avg $977/year across 7 years
Top 42% in TX for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
69
Companies
362
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$159
2023
$392
2022
$514
2021
$1,303
2020
$983
2019
$1,581
2018
$1,909
Payments by company (2024)
TAIHO ONCOLOGY, INC.
$58
Celgene Corporation
$52
Daiichi Sankyo Inc.
$25
Janssen Biotech, Inc.
$24
Top 3 companies account for 85.2% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$976
Merck Sharp & Dohme Corporation
$554
E.R. Squibb & Sons, L.L.C.
$398
Celgene Corporation
$328
TerSera Therapeutics LLC
$300
Lilly USA, LLC
$271
AstraZeneca Pharmaceuticals LP
$263
Janssen Biotech, Inc.
$233
Takeda Pharmaceuticals U.S.A., Inc.
$187
Taiho Oncology, Inc.
$184
Genentech USA, Inc.
$180
Bayer HealthCare Pharmaceuticals Inc.
$155
PFIZER INC.
$154
Novartis Pharmaceuticals Corporation
$153
Daiichi Sankyo Inc.
$147
Verastem, Inc.
$135
GENZYME CORPORATION
$118
Mylan Institutional Inc.
$95
INSYS Therapeutics Inc
$91
TAIHO ONCOLOGY, INC.
$87
Exelixis Inc.
$77
AMAG Pharmaceuticals, Inc.
$77
Clovis Oncology, Inc.
$76
Myovant Sciences Inc.
$70
Rigel Pharmaceuticals, Inc.
$69
Pharmacyclics LLC, An AbbVie Company
$67
Pharmacosmos Therapeutics Inc.
$65
Teva Pharmaceuticals USA, Inc.
$59
Ipsen Biopharmaceuticals, Inc
$58
Regeneron Healthcare Solutions, Inc.
$57
Boehringer Ingelheim Pharmaceuticals, Inc.
$57
TESARO, Inc.
$57
Janssen Pharmaceuticals, Inc
$53
Octapharma USA, Inc.
$49
Myriad Genetic Laboratories, Inc.
$46
Kyowa Kirin, Inc.
$46
Eisai Inc.
$44
Seagen Inc.
$43
Coherus Biosciences Inc.
$41
PUMA BIOTECHNOLOGY, INC.
$40
Merck Sharp & Dohme LLC
$40
EISAI INC.
$40
JAZZ PHARMACEUTICALS INC.
$37
BeiGene USA, Inc.
$37
EMD Serono, Inc.
$35
Shield Therapeutics Inc
$33
Secura Bio, Inc.
$31
Organon LLC
$31
Dova Pharmaceuticals
$29
Medtronic USA, Inc.
$29
Puma Biotechnology, Inc.
$29
Sysmex Inostics Inc
$27
Otsuka America Pharmaceutical, Inc.
$22
Epizyme, Inc.,
$22
Ethicon US, LLC
$21
AbbVie Inc.
$20
R-Pharm US LLC
$20
Mirati Therapeutics, Inc.
$19
Helsinn Therapeutics (U.S.), Inc.
$18
Gilead Sciences, Inc.
$18
GRT US Holding, Inc.
$18
Astellas Pharma US Inc
$15
Advanced Accelerator Applications
$15
MEDELA LLC
$14
Boston Scientific Corporation
$13
Emmaus Medical, Inc.
$13
GlaxoSmithKline, LLC.
$13
Seattle Genetics, Inc.
$12
APO-PHARMA USA, INC.
$12
Top 3 companies account for 28.2% of all-time payments
Associated products mentioned in payments ›
ABECMA · ACCRUFER · ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · Abraxane · Alecensa · BENDEKA · BRUKINSA · Balversa · Bavencio · CHANTIX · CYRAMZA · Cabometyx · Copiktra · DEFERIPRONE · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · Echelon Circular · Endari · Enhertu · Erleada · FERAHEME · Farydak · Fulphila · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INQOVI · INREBIC · Idhifa · Imbruvica · Ixempra · JADENU · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUX-Dx Insertable Cardiac Monitor · LYNPARZA · Lenvima · Lonsurf · Lutathera · MEKINIST · MVASI · MYRISK · Monoferric · NERLYNX · NEXPLANON · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · ONUREG · OPDIVO · ORGOVYX · OSTEOCOOL RF ABLATION · Ogivri · PADCEV · PANZYGA · PIQRAY · POTELIGEO · PROMACTA · Polivy · Pomalyst · Prolia · Qutenza · REBLOZYL · RETACRIT · RYBREVANT · Revlimid · Rubraca · SANCUSO · SANDOSTATIN LAR · SOMATULINE DEPOT · SPRYCEL · SYNDROS · Somatuline Depot · Stivarga · TAGRISSO · TAZVERIK · TECENTRIQ · TREMFYA · Tavalisse · Tecentriq · Trodelvy · Udenyca · VENCLEXTA · VERZENIO · VYXEOS · Vectibix · Vitrakvi · XALKORI · XARELTO · XGEVA · XOSPATA · Xermelo · ZEJULA · ZOLADEX · Zoladex · myRisk
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Medical oncologists in nearby ZIP areas
174
County median income
$113,409
Nearest hospital to ZIP centroid (approximate)
MEMORIAL HERMANN KATY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Riaz is a mixed practice specialist, with moderate Medicare volume, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Riaz experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Riaz performed 5,820 denosumab injection (prolia/xgeva) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Riaz receive payments from pharmaceutical companies?
Yes. Dr. Riaz received a total of $6,841 from 69 companies across 362 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Riaz's costs compare to other medical oncologists in Katy?
Dr. Riaz's average Medicare payment per service is $20. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Riaz) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Katy
Browse medical oncologists in Katy ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology